COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
Authors
Lee, L. Y. W.Cazier, J. B.
Starkey, T.
Briggs, S. E. W.
Arnold, R.
Bisht, V.
Booth, S.
Campton, N. A.
Cheng, V. W. T.
Collins, G.
Curley, H. M.
Earwaker, P.
Fittall, M. W.
Gennatas, S.
Goel, A.
Hartley, S.
Hughes, D. J.
Kerr, D.
Lee, A. J. X.
Lee, Rebecca J
Lee, S. M.
McKenzie, H.
Middleton, C. P.
Murugaesu, N.
Newsom-Davis, T.
Olsson-Brown, A. C.
Palles, C.
Powles, T.
Protheroe, E. A.
Purshouse, K.
Sharma-Oates, A.
Sivakumar, S.
Smith, A. J.
Topping, O.
Turnbull, C. D.
Varnai, C
Briggs, A. D. M.
Middleton, G.
Kerr, R.
Affiliation
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Department of Oncology, University of Oxford, Oxford, UK; University Hospitals Birmingham, Birmingham, UK.Issue Date
2020
Metadata
Show full item recordAbstract
Background: Patients with cancer are purported to have poor COVID-19 outcomes. However, cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour subtypes. The aim of this study was to investigate COVID-19 risk according to tumour subtype and patient demographics in patients with cancer in the UK. Methods: We compared adult patients with cancer enrolled in the UK Coronavirus Cancer Monitoring Project (UKCCMP) cohort between March 18 and May 8, 2020, with a parallel non-COVID-19 UK cancer control population from the UK Office for National Statistics (2017 data). The primary outcome of the study was the effect of primary tumour subtype, age, and sex and on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevalence and the case-fatality rate during hospital admission. We analysed the effect of tumour subtype and patient demographics (age and sex) on prevalence and mortality from COVID-19 using univariable and multivariable models. Findings: 319 (30�6%) of 1044 patients in the UKCCMP cohort died, 295 (92�5%) of whom had a cause of death recorded as due to COVID-19. The all-cause case-fatality rate in patients with cancer after SARS-CoV-2 infection was significantly associated with increasing age, rising from 0�10 in patients aged 40-49 years to 0�48 in those aged 80 years and older. Patients with haematological malignancies (leukaemia, lymphoma, and myeloma) had a more severe COVID-19 trajectory compared with patients with solid organ tumours (odds ratio [OR] 1�57, 95% CI 1�15-2�15; p<0�0043). Compared with the rest of the UKCCMP cohort, patients with leukaemia showed a significantly increased case-fatality rate (2�25, 1�13-4�57; p=0�023). After correction for age and sex, patients with haematological malignancies who had recent chemotherapy had an increased risk of death during COVID-19-associated hospital admission (OR 2�09, 95% CI 1�09-4�08; p=0�028). Interpretation: Patients with cancer with different tumour types have differing susceptibility to SARS-CoV-2 infection and COVID-19 phenotypes. We generated individualised risk tables for patients with cancer, considering age, sex, and tumour subtype. Our results could be useful to assist physicians in informed risk-benefit discussions to explain COVID-19 risk and enable an evidenced-based approach to national social isolation policies.Citation
Lee LYW, Cazier J-B, Starkey T, Briggs SEW, Arnold R, Bisht V, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. The Lancet Oncology. 2020.Journal
Lancet OncologyDOI
10.1016/s1470-2045(20)30442-3PubMed ID
32853557Additional Links
https://dx.doi.org/10.1016/s1470-2045(20)30442-3Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/s1470-2045(20)30442-3
Scopus Count
Collections
Related articles
- Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study.
- Authors: Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, Lu H, Liu J, Yang J, Dong Y, Pan D, Shu C, Li J, Wei J, Huang Y, Peng L, Wu M, Zhang R, Wu B, Li Y, Cai L, Li G, Zhang T, Wu G
- Issue date: 2020 Jul
- COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.
- Authors: Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, Chackathayil J, Cheng VW, Curley HM, Fittall MW, Freeman-Mills L, Gennatas S, Goel A, Hartley S, Hughes DJ, Kerr D, Lee AJ, Lee RJ, McGrath SE, Middleton CP, Murugaesu N, Newsom-Davis T, Okines AF, Olsson-Brown AC, Palles C, Pan Y, Pettengell R, Powles T, Protheroe EA, Purshouse K, Sharma-Oates A, Sivakumar S, Smith AJ, Starkey T, Turnbull CD, Várnai C, Yousaf N, UK Coronavirus Monitoring Project Team, Kerr R, Middleton G
- Issue date: 2020 Jun 20
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
- Authors: Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranel J, De Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, Grossi F, Grosso F, Intagliata S, La Verde N, Liu SV, Mazieres J, Mercadante E, Michielin O, Minuti G, Moro-Sibilot D, Pasello G, Passaro A, Scotti V, Solli P, Stroppa E, Tiseo M, Viscardi G, Voltolini L, Wu YL, Zai S, Pancaldi V, Dingemans AM, Van Meerbeeck J, Barlesi F, Wakelee H, Peters S, Horn L, TERAVOLT investigators
- Issue date: 2020 Jul
- Determinants of COVID-19 disease severity in patients with cancer.
- Authors: Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, Bogler Y, Caldararo M, Figueroa CJ, Glickman MS, Joanow A, Kaltsas A, Lee YJ, Lucca A, Mariano A, Morjaria S, Nawar T, Papanicolaou GA, Predmore J, Redelman-Sidi G, Schmidt E, Seo SK, Sepkowitz K, Shah MK, Wolchok JD, Hohl TM, Taur Y, Kamboj M
- Issue date: 2020 Aug
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
- Authors: Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B
- Issue date: 2020 Mar 28